Genentech
AskBiography Logo   Latest News  Follow Us on Twitter  Follow Us on Google Buzz  Became Fan - Facebook  Subscribe to RSSRSS   Bookmark and Share

Genentech

Company nameGenentech, Inc.
Company typeWholly-owned subsidiary of Roche
SloganIn business for life
IndustryBiotechnology
Founded1976
HeadquartersSouth San Francisco, California, USA
Key peoplePascal Soriot, CEO
Hal Barron, Product Development
Steve Krognes, CFO
Richard H. Scheller, Research and Early Development
Ian T. Clark, Commercial
Patrick Y. Yang, Product Operations
Todd Pierce, CIO
Steve Grossman, HR North America
Rick Kentz, Legal
Marc Tessier-Lavigne, Research
Denise Smith-Hams, HR, Genentech
Chris Castro, Corporate Relations, North America
ProductsActivase/Cathflo, Nutropin, Pulmozyme, Rituxan, Herceptin, TNKase, Xolair, Avastin, Tarceva, Lucentis
Employeesc. 11,000 (December 31, 2008)

     Home | Company | Genentech



Genentech Inc., or Genetic Engineering Technology, Inc., is a biotechnology corporation, founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert Boyer. It is considered to have founded the biotechnology industry. One of its founders, Boyer, is considered to be a pioneer in the field of recombinant DNA technology. In 1973, Boyer and his colleague Stanley Norman Cohen demonstrated that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia, Swanson contacted Boyer to found the company. Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977. David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin in 1978.

As of March 2008, Genentech employed more than 11,000 people and Arthur D. Levinson was the chairman and CEO. The Swiss pharmaceutical conglomerate Hoffmann-La Roche now completely owns Genentech after completing its purchase on March 26, 2009 for approximately $46.8 billion.

Latest News : Genentech : Tweet this RSS

Want to Genentech latest news on your twitter account???   sign in with twitter
Genentech     sign in with twitter   ||  Company     sign in with twitter   ||  Economy     sign in with twitter
Genentech lymphoma drug receives FDA approval for maintenance use - Pharmaceutical Business Review Tweet this news
Pharmaceutical Business Review---Genentech- has received approval from the US Food and Drug Administration (FDA) for Rituxan (rituximab), as a maintenance treatment for patients with ... - Date : Mon, 31 Jan 2011 06:41:25 GMT+00:00
FDA warns Genentech about Boniva ad with Sally Field - Bizjournals.com Tweet this news
Bizjournals.com--A print advertisement featuring actress Sally Field for -Genentech- Inc.'s osteoporosis treatment Boniva is under fire from the Food and Drug Administration ... - Date : Wed, 26 Jan 2011 22:57:24 GMT+00:00
Genentech: Advanced skin cancer treatment boosts survival rate - Drug Store News Tweet this news
Drug Store News--Patients taking an investigational drug made by -Genentech- for advanced skin cancer fared better than those receiving standard treatments, according to ... - Date : Thu, 20 Jan 2011 18:18:27 GMT+00:00
Genentech Appeals Proposed Withdrawal Of Breast Cancer Drug - Medical News Today (press release) Tweet this news
Medical News Today (press release)--Roche's -Genentech- on Tuesday formally petitioned FDA to reconsider its decision to revoke approval of Avastin as a treatment for breast cancer, ... - Date : Thu, 20 Jan 2011 13:08:18 GMT+00:00
Caltrain's Demise Could Mean Gridlock and Pollution for Peninsula - Patch Tweet this news
Patch--“Our mobility up and down the Peninsula cannot survive without Caltrain,” said -Genentech- Associate Director of Transportation Dan McCoy. ... - Date : Sat, 22 Jan 2011 22:28:16 GMT+00:00
Genentech says melanoma drug met study goal - Bloomberg Tweet this news
Bloomberg--By AP NEW YORK (AP) � The drugmaker -Genentech- said its cancer drug RG7204 improved survival for people with melanoma, and slowed the progress of the ... - Date : Wed, 19 Jan 2011 13:02:45 GMT+00:00
Genentech appeals FDA's plan to pull Avastin off market - Drug Store News Tweet this news
Drug Store News--NEW YORK � Drug maker -Genentech- is hoping to keep a breast cancer treatment on the market as the Food and Drug Administration considers whether to revoke ... - Date : Thu, 20 Jan 2011 18:18:23 GMT+00:00
Genentech's Drug Candidate Shows Survival Benefit In Advanced Skin Cancer - RTT News Tweet this news
RTT News--PK: News ) biotechnology business -Genentech- Wednesday stated that its investigational drug candidate RG7204 showed significant survival benefit in a phase ... - Date : Wed, 19 Jan 2011 11:45:00 GMT+00:00
Prescriptions: Genentech Appeals Avastin Decision - New York Times (blog) Tweet this news
New York Times (blog)---Genentech- on Tuesday formally asked the Food and Drug Administration to overturn last month's decision revoking the approval of the drug ... - Date : Tue, 18 Jan 2011 20:15:33 GMT+00:00
ThyssenKrupp's Hippe to take over as Roche CFO - Reuters Africa Tweet this news
Reuters Africa---...- is joining Roche as the pharma industry faces some of its toughest challenges and as the group tries to reduce debt after its -Genentech- buyout. ... - Date : Mon, 17 Jan 2011 06:20:21 GMT+00:00



Privacy | Sitemap